体内ANGPTL3基因编辑用于持久降低血脂
In Vivo CRISPR Base Editing of ANGPTL3 for Durable Lipid Lowering
研究团队使用CRISPR腺嘌呤碱基编辑器在非人灵长类动物中实现了持久的ANGPTL3基因编辑,降低了90%的循环ANGPTL3蛋白水平,同时显著降低了LDL-C和甘油三酯水平。这些结果为治疗高脂血症提供了新的治疗策略。
研究团队展示了CRISPR基因编辑在降低血脂方面的持久效果,为治疗高脂血症提供了新思路。
- Article
- Published: 06 November 2026
- Taiji Mizoguchi1,
- Jamie E. DeNizio1,
- Alexandra C. Chadwick1,
- Anne Marie Mazzola1,
- Maxwell P. Brown1,
- Shashank Mishra1,
- Manashree Damle1,
- Yuri Matsumoto1,
- Victoria Neang1,
- Ryan Garrity1,
- Manini Mantri1,
- Joy Oshoname Olorife1,
- Hui-Ting Hsu1,
- Vian Peshdary1,
- Estela Shabani1,
- John D. Ganey1,
- Ryan Santos1,
- Anthony Federico1,
- Sara P. Garcia1,
- Pengying Hao1,
- Yue Wu1,
- Zachary Glass1,
- Lisa N. Kasiewicz1,
- Caroline Summers1,
- Athul Sanjeev1,
- Kui Wang1,
- Steven D. Briscoe1,
- Robert S. Rosenson ORCID: orcid.org/0000-0002-5599-06332,
- Christopher J. Cheng ORCID: orcid.org/0009-0008-8092-51991,
- Ellen Rohde1,
- Joseph Biedenkapp1,
- Victor Farutin1,
- Andrew M. Bellinger1,3,
- Kiran Musunuru ORCID: orcid.org/0000-0003-3298-03684,5,6,
- Sekar Kathiresan1,
- Troy Lister1,
- Kallanthottathil G. Rajeev1,
- Richard G. Lee1 &
- …
- Amit V. Khera ORCID: orcid.org/0000-0001-6535-58391
Nature (2026) Cite this article
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Abstract
Circulating concentrations of low-density lipoprotein cholesterol (LDL-C) and triglyceride-rich lipoproteins are leading risk factors for atherosclerotic cardiovascular disease1. Despite several approved lipid-lowering medications, most patients fail to achieve target lipid levels under the chronic care treatment model2,3. Here, we describe a potential single-course treatment in which an infusion of guide RNA and mRNA encoding a CRISPR adenine base editor—encapsulated within a GalNAc–lipid nanoparticle—leads to durable, liver-selective inactivation of angiopoietin-like 3 (ANGPTL3), a known driver of increased LDL-C and triglyceride concentrations. Analyses in human liver cells in vitro confirmed that the base editor introduces a DNA base-pair change at the target ANGPTL3 locus with no detectable off-target editing at any of approximately 3000 candidate sites or treatment-related structural variants. Targeted ANGPTL3 inactivation in nonhuman primates was well-tolerated and led to a > 90% mean reduction in circulating ANGPTL3 protein, with durability confirmed out to 3 years following a single dose. In mouse and nonhuman primate models of hyperlipidemia, gene inactivation was associated with reductions of approximately 40 to 50% in LDL-C and 50 to 70% in triglycerides. These results provided the scientific foundation for initiation of an ongoing first-in-human clinical trial in patients with refractory hyperlipidemia syndromes.
Author information
Authors and Affiliations
Verve Therapeutics, Inc. (a wholly owned subsidiary of Eli Lilly and Company), Boston, MA, USA
Taiji Mizoguchi, Jamie E. DeNizio, Alexandra C. Chadwick, Anne Marie Mazzola, Maxwell P. Brown, Shashank Mishra, Manashree Damle, Yuri Matsumoto, Victoria Neang, Ryan Garrity, Manini Mantri, Joy Oshoname Olorife, Hui-Ting Hsu, Vian Peshdary, Estela Shabani, John D. Ganey, Ryan Santos, Anthony Federico, Sara P. Garcia, Pengying Hao, Yue Wu, Zachary Glass, Lisa N. Kasiewicz, Caroline Summers, Athul Sanjeev, Kui Wang, Steven D. Briscoe, Christopher J. Cheng, Ellen Rohde, Joseph Biedenkapp, Victor Farutin, Andrew M. Bellinger, Sekar Kathiresan, Troy Lister, Kallanthottathil G. Rajeev, Richard G. Lee & Amit V. Khera
Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Robert S. Rosenson
GV Management Company, LLC, Boston, MA, USA
Andrew M. Bellinger
Cardiovascular Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
Kiran Musunuru
Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
Kiran Musunuru
Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
Kiran Musunuru
Authors
- Taiji Mizoguchi
- Jamie E. DeNizio
- Alexandra C. Chadwick
- Anne Marie Mazzola
- Maxwell P. Brown
- Shashank Mishra
- Manashree Damle
- Yuri Matsumoto
- Victoria Neang
- Ryan Garrity
- Manini Mantri
- Joy Oshoname Olorife
- Hui-Ting Hsu
- Vian Peshdary
- Estela Shabani
- John D. Ganey
- Ryan Santos
- Anthony Federico
- Sara P. Garcia
- Pengying Hao
- Yue Wu
- Zachary Glass
- Lisa N. Kasiewicz
- Caroline Summers
- Athul Sanjeev
- Kui Wang
- Steven D. Briscoe
- Robert S. Rosenson
- Christopher J. Cheng
- Ellen Rohde
- Joseph Biedenkapp
- Victor Farutin
- Andrew M. Bellinger
- Kiran Musunuru
- Sekar Kathiresan
- Troy Lister
- Kallanthottathil G. Rajeev
- Richard G. Lee
- Amit V. Khera
Corresponding author
Correspondence to Amit V. Khera.
About this article
Cite this article
Mizoguchi, T., DeNizio, J.E., Chadwick, A.C. et al. In Vivo CRISPR Base Editing of ANGPTL3 for Durable Lipid Lowering. Nature (2026). https://doi.org/10.1038/s41586-026-11233-9
Received: 08 April 2025
Accepted: 01 October 2026
Published: 06 November 2026
DOI: https://doi.org/10.1038/s41586-026-11233-9
来源:Nature 综合主刊 · nature.com